There are currently 1 active clinical trials seeking participants for Atypical Hemolytic Uremic Syndrome (aHUS) research studies. The states with the highest number of trials for Atypical Hemolytic Uremic Syndrome (aHUS) participants are North Carolina, Georgia, Ohio and Massachusetts.
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Recruiting
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/06/2025
Locations: North American call center (NACC), Boston, Massachusetts
Conditions: Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)